ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO537

Kidney Function Predicts New-Onset Cardiorenal Events and Mortality in Primary Aldosteronism: Approach of the 2021 Race-Free eGFR Equation

Session Information

Category: Hypertension and CVD

  • 1602 Hypertension and CVD: Clinical


  • Lai, Chun-Fu, National Taiwan University Hospital, Taipei, Taiwan
  • Lin, Yen-Hung, National Taiwan University Hospital, Taipei, Taiwan
  • Wu, Vincent, National Taiwan University Hospital, Taipei, Taiwan

Group or Team Name

  • Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group.

Individuals with primary aldosteronism (PA) exhibit glomerular hyperfiltration, which may conceal underlying kidney damage. We aimed to investigate whether baseline estimated glomerular filtration rate (eGFR) is associated with cardiovascular outcomes in this population.


This observational cohort study enrolled 760 coronary artery disease-naïve patients diagnosed with PA between January 1, 2007 and December 31, 2018 (male, 45%; mean age, 52.3 ± 11.9 years). The baseline eGFR was calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, which includes serum creatinine and cystatin C but omits the race variable. Outcomes were composite cardiovascular events (total death, non-fatal myocardial infarction, and coronary revascularization procedure), all-cause mortality, and adverse kidney events.


During a mean follow-up of 5.8 ± 3.2 years, new-onset composite cardiovascular events occurred in 47 patients, with a crude incidence rate of 10.9 per 1,000 person-years. Multivariable Cox proportional hazards analysis showed that baseline eGFR was independently associated with composite cardiovascular events (hazard ratio [HR], 0.98 [95% CI, 0.97–0.99]). Penalized splines smoothing in multivariable regression analysis demonstrated that the risk of composite cardiovascular events increased negatively and linearly when patients had a baseline eGFR less than 85 mL/min/1.73m2. Patients with baseline eGFR <85 mL/min/1.73m2 were independently associated with higher risks of composite cardiovascular events (HR, 2.39 [95% CI, 1.16–4.93]), mortality (HR, 4.63 [95% CI, 1.59–13.46]), and adverse kidney events (sub-distribution HR, 5.96 [95% CI, 3.69–9.62], with mortality as a competing risk). (Figure 1A-C)


Our data support interpreting baseline eGFR as a predictor for new-onset adverse cardiorenal events and emphasizes the importance of the early detection of kidney function impairment in hypertensive patients with PA. We also firstly point to the validity of the 2021 race-free CKD-EPI equation in patents with PA.

Figure 1. Clinical outcomes of interest in patients stratified by the baseline kidney function.


  • Government Support – Non-U.S.